Serum sCTLA-4 levels and clinical manifestations in ankylosing spondylitis patients

ÇETİNTEPE S. P., ŞENTÜRK T., Sargin G., AYDIN N.

EUROPEAN JOURNAL OF RHEUMATOLOGY, cilt.5, sa.2, ss.115-117, 2018 (ESCI) identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 5 Sayı: 2
  • Basım Tarihi: 2018
  • Doi Numarası: 10.5152/eurjrheum.2018.17114
  • Dergi Adı: EUROPEAN JOURNAL OF RHEUMATOLOGY
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.115-117
  • Hacettepe Üniversitesi Adresli: Evet

Özet

Objective: T cell abnormal activation is thought to have a main role in the etiology of ankylosing spondylitis (AS). While cytotoxic T lymphocyte-associated molecule-4 (CTLA-4) is suppressing the immune system, in previous studies serum soluble CTLA-4 (sCTLA-4) was detected at high amounts in autoimmune disorders. We sought to evaluate the association between soluble CTLA-4 in serum and disease activity in AS patients.